Artykuły w czasopismach: „XP”

1

Cowham, R. "To XP or not to XP?" ITNOW 47, nr 2 (1.03.2005): 16. http://dx.doi.org/10.1093/itnow/bwi030.

Style APA, Harvard, Vancouver, ISO itp.

2

Fischer, R., M. Uhl i H. Vonach. "Nb93(n,xp),Agnat(n,xp), andInnat(n,xp) reactions at 14.1 MeV". Physical Review C 37, nr 2 (1.02.1988): 578–86. http://dx.doi.org/10.1103/physrevc.37.578.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Litts, Thom, i Jeff Kopaska. "RIP XP". Fisheries 39, nr 4 (3.04.2014): 151. http://dx.doi.org/10.1080/03632415.2014.893871.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Sonia, Archana Singhal i Hema Banati. "FISA-XP". ACM SIGSOFT Software Engineering Notes 39, nr 3 (4.06.2014): 1–14. http://dx.doi.org/10.1145/2597716.2597728.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

Lee, Jeeyun, Do Hoon Lim, Sung Kim, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim i in. "Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial". Journal of Clinical Oncology 30, nr 3 (20.01.2012): 268–73. http://dx.doi.org/10.1200/jco.2011.39.1953.

Pełny tekst źródła

Streszczenie:

Purpose The ARTIST (Adjuvant Chemoradiation Therapy in Stomach Cancer) trial was the first study to our knowledge to investigate the role of postoperative chemoradiotherapy therapy in patients with curatively resected gastric cancer with D2 lymph node dissection. This trial was designed to compare postoperative treatment with capecitabine plus cisplatin (XP) versus XP plus radiotherapy with capecitabine (XP/XRT/XP). Patients and Methods The XP arm received six cycles of XP (capecitabine 2,000 mg/m2 per day on days 1 to 14 and cisplatin 60 mg/m2 on day 1, repeated every 3 weeks) chemotherapy. The XP/XRT/XP arm received two cycles of XP followed by 45-Gy XRT (capecitabine 1,650 mg/m2 per day for 5 weeks) and two cycles of XP. Results Of 458 patients, 228 were randomly assigned to the XP arm and 230 to the XP/XRT/XP arm. Treatment was completed as planned by 75.4% of patients (172 of 228) in the XP arm and 81.7% (188 of 230) in the XP/XRT/XP arm. Overall, the addition of XRT to XP chemotherapy did not significantly prolong disease-free survival (DFS; P = .0862). However, in the subgroup of patients with pathologic lymph node metastasis at the time of surgery (n = 396), patients randomly assigned to the XP/XRT/XP arm experienced superior DFS when compared with those who received XP alone (P = .0365), and the statistical significance was retained at multivariate analysis (estimated hazard ratio, 0.6865; 95% CI, 0.4735 to 0.9952; P = .0471). Conclusion The addition of XRT to XP chemotherapy did not significantly reduce recurrence after curative resection and D2 lymph node dissection in gastric cancer. A subsequent trial (ARTIST-II) in patients with lymph node–positive gastric cancer is planned.

Style APA, Harvard, Vancouver, ISO itp.

6

Ivorra, Wilfrid. "Sur les équations xp+2βyp= z2et xp+2βyp= 2z2". Acta Arithmetica 108, nr 4 (2003): 327–38. http://dx.doi.org/10.4064/aa108-4-3.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Fassihi, Hiva, Mieran Sethi, Heather Fawcett, Jonathan Wing, Natalie Chandler, Shehla Mohammed, Emma Craythorne i in. "Deep phenotyping of 89 xeroderma pigmentosum patients reveals unexpected heterogeneity dependent on the precise molecular defect". Proceedings of the National Academy of Sciences 113, nr 9 (16.02.2016): E1236—E1245. http://dx.doi.org/10.1073/pnas.1519444113.

Pełny tekst źródła

Streszczenie:

Xeroderma pigmentosum (XP) is a rare DNA repair disorder characterized by increased susceptibility to UV radiation (UVR)-induced skin pigmentation, skin cancers, ocular surface disease, and, in some patients, sunburn and neurological degeneration. Genetically, it is assigned to eight complementation groups (XP-A to -G and variant). For the last 5 y, the UK national multidisciplinary XP service has provided follow-up for 89 XP patients, representing most of the XP patients in the United Kingdom. Causative mutations, DNA repair levels, and more than 60 clinical variables relating to dermatology, ophthalmology, and neurology have been measured, using scoring systems to categorize disease severity. This deep phenotyping has revealed unanticipated heterogeneity of clinical features, between and within complementation groups. Skin cancer is most common in XP-C, XP-E, and XP-V patients, previously considered to be the milder groups based on cellular analyses. These patients have normal sunburn reactions and are therefore diagnosed later and are less likely to adhere to UVR protection. XP-C patients are specifically hypersensitive to ocular damage, and XP-F and XP-G patients appear to be much less susceptible to skin cancer than other XP groups. Within XP groups, different mutations confer susceptibility or resistance to neurological damage. Our findings on this large cohort of XP patients under long-term follow-up reveal that XP is more heterogeneous than has previously been appreciated. Our data now enable provision of personalized prognostic information and management advice for each XP patient, as well as providing new insights into the functions of the XP proteins.

Style APA, Harvard, Vancouver, ISO itp.

8

Kunwar, Sundar. "Enabling and Limiting factors in eXtreme Programming (XP) with Evaluation Framework". SCITECH Nepal 14, nr 1 (9.09.2019): 50–62. http://dx.doi.org/10.3126/scitech.v14i1.25534.

Pełny tekst źródła

Streszczenie:

As agile software development methodologies are used in many domains and come with different shapes and sizes, it is one of the complex human endeavors. Extreme Programming (XP) is one of the well-known agile software development methodologies and is driven by a set of values including simplicity, communication, feedback and courage, but lacks the mechanism to measure these values demanding the evaluation framework to make it measurable and attainable. The main aim of this study is to build the software process improvement model that can be used for evaluating XP values and practices. The proposed XP evaluation framework in this study is XP focused and evaluates the XP project, product and practices. The XP evaluation framework is a collection of some new and validated metrics used for evaluating XP projects, XP practices, XP products and some additional factors concerned with XP. The evaluation framework for extreme programming is basically based on the assessment and evaluation of various project characteristics, extreme programming characteristics, product characteristics and other additional characteristics. The metrics used for assessments and evaluations of XP are designed to be simple, precise, understandable, economical, timely, consistent, accountable, unambiguous, suitable and reliable.

Style APA, Harvard, Vancouver, ISO itp.

9

Maxmen, Amy. "XP mutant power!" Journal of Experimental Medicine 206, nr 13 (30.11.2009): 2856. http://dx.doi.org/10.1084/jem.20613iti2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

RapićOtrin, Vesna, Isao Kuraoka, Tiziana Nardo, Mary McLenigan, A. P. M. Eker, Miria Stefanini, Arthur S. Levine i Richard D. Wood. "Relationship of the Xeroderma Pigmentosum Group E DNA Repair Defect to the Chromatin and DNA Binding Proteins UV-DDB and Replication Protein A". Molecular and Cellular Biology 18, nr 6 (1.06.1998): 3182–90. http://dx.doi.org/10.1128/mcb.18.6.3182.

Pełny tekst źródła

Streszczenie:

ABSTRACT Cells from complementation groups A through G of the heritable sun-sensitive disorder xeroderma pigmentosum (XP) show defects in nucleotide excision repair of damaged DNA. Proteins representing groups A, B, C, D, F, and G are subunits of the core recognition and incision machinery of repair. XP group E (XP-E) is the mildest form of the disorder, and cells generally show about 50% of the normal repair level. We investigated two protein factors previously implicated in the XP-E defect, UV-damaged DNA binding protein (UV-DDB) and replication protein A (RPA). Three newly identified XP-E cell lines (XP23PV, XP25PV, and a line formerly classified as an XP variant) were defective in UV-DDB binding activity but had levels of RPA in the normal range. The XP-E cell extracts did not display a significant nucleotide excision repair defect in vitro, with either UV-irradiated DNA or a uniquely placed cisplatin lesion used as a substrate. Purified UV-DDB protein did not stimulate repair of naked DNA by DDB− XP-E cell extracts, but microinjection of the protein into DDB−XP-E cells could partially correct the repair defect. RPA stimulated repair in normal, XP-E, or complemented extracts from other XP groups, and so the effect of RPA was not specific for XP-E cell extracts. These data strengthen the connection between XP-E and UV-DDB. Coupled with previous results, the findings suggest that UV-DDB has a role in the repair of DNA in chromatin.

Style APA, Harvard, Vancouver, ISO itp.

11

Stanojevic, Jelena. "On estimation of high quantiles for certain classes of distributions". Yugoslav Journal of Operations Research 25, nr 2 (2015): 299–312. http://dx.doi.org/10.2298/yjor130606013s.

Pełny tekst źródła

Streszczenie:

We investigate the rate of convergence of the direct-simulation estimator ? ?xp(n) of a large quantile xp of the Pareto and Gamma distributions. The upper bound of the probability P{|?xp(n)- xp|>? is determined.

Style APA, Harvard, Vancouver, ISO itp.

12

Suman, AHM Khairul Imam, Khadija Begum, Kaniz Rahman, Abu Mohammed Talukder, SM Matiur Rahman, Md Akmat Ali, Nusrath Jahan Hoque i Mohammad Morshad Alam. "Association of Xanthelasma palpebrarum (XP) with cardiovascular disease (CVD) risk factors". Asian Journal of Medical and Biological Research 5, nr 4 (3.02.2020): 324–29. http://dx.doi.org/10.3329/ajmbr.v5i4.45271.

Pełny tekst źródła

Streszczenie:

Xanthelasma palpebrarum (XP) is the most common cutaneous xanthoma occurs over or surrounding the eyelids in yellowish color and various shapes. The objective of this study was to describe the status of cardiovascular disease risk factors in XP patients and determine their association with XP. A case-control study was conducted among 81 cases (have XP) and 81 controls (no XP) among patients attended for cardiac check-up between January 2019 to July 2019 at Ad-Din Women's Medical College Hospital, Dhaka, Bangladesh. Among 162 subjects were interviewed in our study, majority were female (62.3%). XP were found more prevalent among female and several cardiac risk factors were significantly associated with XP. The chi-square analysis indicates gender (p=0.035), BMI (p=0.01), Angina history (p=0.008), and serum LDL (p=0.024) were significantly associated with presence of XP. A higher percentage of patients with high total serum cholesterol, TG levels, and LDL was observed in patients with XP in compared to control group. Our study reveals an increased presence of cardiovascular disease risk factors among patients with xanthelasma. Moreover, a statistically significant association of gender, BMI, angina history, and serum LDL with XP were observed. Asian J. Med. Biol. Res. June 2019, 5(4): 324-329

Style APA, Harvard, Vancouver, ISO itp.

13

Vaz-Garcia, Eduarda Santiago, Victor Talarico Leal Vieira, Natasha Pereira da Silva Ferreira Petitet, Edson Jorge Lima Moreira, Hélio Pereira Lopes, Carlos Nelson Elias, Emmanuel João Nogueira Leal Silva i Henrique dos Santos Antunes. "Mechanical Properties of Anatomic Finishing Files: XP-Endo Finisher and XP-Clean". Brazilian Dental Journal 29, nr 2 (marzec 2018): 208–13. http://dx.doi.org/10.1590/0103-6440201801903.

Pełny tekst źródła

Streszczenie:

Abstract The aim of the present study was to evaluate the cyclic fatigue of two anatomic finishing files: XP-Endo Finisher and XP-Clean. Roughness pattern and the micro-hardness of the files were also assessed. Instruments were subjected to cyclic fatigue resistance measuring the time to fracture in an artificial stainless-steel canal with a 60° angle and a 5-mm radius of curvature. The fracture surface of all fragments was examined with a scanning electron microscope. The roughness of the working parts was quantified by using a profilometer and the micro-hardness test was carried out using a Vickers hardness tester. Results were statistically analyzed using a student´s t-test at a significance level of P < 0.05. Weibull analysis was also performed. XP-Endo Finisher presented significantly longer cyclic fatigue life than XP-Clean instruments (P<0.05). XP-Endo Finisher was able to withstand 1000% more cycles to fracture when compared to XP-Clean instruments. SEM visual inspection of the fracture surfaces revealed fractographic characteristics of ductile fracture in all tested instruments; wide-ranging forms of dimples were identified and no plastic deformation in the helical shaft of the fractured instruments was observed. When mean life was compared XP-Endo Finisher lasted longer than XP-Clean with a probability of 99.9%. XP-Endo Finisher instruments also exhibited significantly lower roughness than XP-Clean instruments (P<0.05). No differences in the micro-hardness was observed between the files (P>0.05). It can be concluded that XP-Endo Finisher instruments showed improved performance when compared with XP-Clean instruments, demonstrating higher cyclic fatigue resistance and lower roughness.

Style APA, Harvard, Vancouver, ISO itp.

14

Price, Vera H. "Trichothiodystrophy: Current Concepts". Journal of Cutaneous Medicine and Surgery 1, nr 1 (lipiec 1996): 45–49. http://dx.doi.org/10.1177/120347549600100113.

Pełny tekst źródła

Streszczenie:

Background: Trichothiodystrophy (TTD) is a rare, autosomal recessive disorder in which the hair identifies a group of genetic disorders with deficient high-sulfur matrix proteins, and a defect in excision repair of ultraviolet damage in fibroblasts of most patients. TTD patients may be grouped as follows: (1) the major group with defects in the excision repair cross-complementing gene ERCC2, the gene for xeroderma pigmentosum group D (XP-D); (2) those with defects in ERCC3, the gene for XP-B; and (3) those with a repair defect distinct from those in XP-D and XP-B. In contrast to XP patients, TTD patients have no increased frequency of skin cancers. Objective: The article explains the relationship of TTD and XP and helps clarify why TTD patients with defects in the same gene(s) as those with XP do not have increased skin cancers. Methods: Methods include biochemical studies, mutational analysis, and genomic sequence analysis of cell lines from skin biopsies of TTD and XP patients. Results: The ERCC2 gene is a component of the TFIIH complex which controls two distinct DNA-metabolizing processes, transcription initiation and nucleotide excision repair. Conclusion: In TTD, the major defect is in transcription initiation, whereas in XP-D, DNA repair is primarily altered.

Style APA, Harvard, Vancouver, ISO itp.

15

Miao, Junjie, Changchun Chai, Wei Zhang, Yanxing Song i Yintang Yang. "First-Principles Study on Structural, Mechanical, Anisotropic, Electronic and Thermal Properties of III-Phosphides: XP (X = Al, Ga, or In) in the P6422 Phase". Materials 13, nr 3 (4.02.2020): 686. http://dx.doi.org/10.3390/ma13030686.

Pełny tekst źródła

Streszczenie:

The structural, mechanical, electronic, and thermal properties, as well as the stability and elastic anisotropy, of XP (X = Al, Ga, or In) in the P6422 phase were studied via density functional theory (DFT) in this work. P6422-XP (X = Al, Ga, or In) are dynamically and thermodynamically stable via phonon spectra and enthalpy. At 0 GPa, P6422-XP (X = Al, Ga, or In) are more rigid than F 4 ¯ 3 m-XP (X = Al, Ga, or In), of which P6422-XP (X = Al or Ga) are brittle and P6422-InP is ductile. In the same plane (except for (001)-plane), P6422-AlP and P6422-InP exhibit the smallest and the largest anisotropy, respectively, and P6422-XP (X = Al, Ga, or In) is isotropic in the (001)-plane. In addition, Al, Ga, In, and P bonds bring different electrical properties: P6422-InP exhibits a direct band gap (0.42 eV) with potential application for an infrared detector, whereas P6422-XP (X = Al or Ga) exhibit indirect band gap (1.55 eV and 0.86 eV). At high temperature (approaching the melting point), the theoretical minimum thermal conductivities of P6422-XP (X = Al, Ga, or In) are AlP (1.338 W∙m−1∙K−1) > GaP (1.058 W∙m−1∙K−1) > InP (0.669 W∙m−1∙K−1), and are larger than those of F 4 ¯ 3 m-XP (X = Al, Ga, or In). Thus, P6422-XP (X = Al, Ga, or In) have high potential application at high temperature.

Style APA, Harvard, Vancouver, ISO itp.

16

Lee, J., W. Kang, D. Lim, J. Park, Y. Park, H. Lim, T. Sohn, J. Noh, J. Bae i S. Kim. "Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): Safety analysis". Journal of Clinical Oncology 27, nr 15_suppl (20.05.2009): 4537. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.4537.

Pełny tekst źródła

Streszczenie:

4537 Background: Although the adjuvant chemoradiation therapy has gained popularity and has become the standard of care in patients with resected gastric cancer in U.S., the role of chemoradiation therapy after extended D2 dissection has been questioned. We conducted a phase III trial to compare capecitabine/cisplatin (XP) vs XP + radiotherapy (RT) in curatively D2 resected gastric cancer patients in terms of disease free survival and overall survival. Methods: Eligibility criteria were as follows: stage Ib (T1N1, T2bN0) - IV (M1 excluded), curatively ≥ D2 resected gastric adenocarcinoma. XP only: X 2,000 mg/m2/d D1∼14, CDDP 60 mg/m2 D1 repeated every 3 weeks, 6 cycles; XP + RT: X 2,000 mg/m2/d D1∼14, CDDP 60 mg/m2 D1 x 2 cycles ⋄ RT 45 Gy (25 fractions) + X 1,650 mg/m2/d during RT ⋄ X 2,000 mg/m2/d D1∼14, CDDP 60 mg/m2 D1 x 2 cycles. The primary endpoint is 3-year disease-free survival. Results: From October 2004 to April 2008, 458 patients (XP arm: 228 patients; XP/RT arm: 230 patients) were enrolled. In XP arm, 172 (75%) of 228 enrolled patients completed 6 cycles of chemotherapy. In XP + RT arm, 188 (82%) of 230 patients completed the full course of XP 2 cycles - X + RT - XP 2 cycles. Conclusions: Safety and feasibility analysis of the two arms will be reported at the meeting. No significant financial relationships to disclose.

Style APA, Harvard, Vancouver, ISO itp.

17

Fernández-Sánchez, Javier. "Against a clausal ellipsis account of all stripping strings in Spanish". Poznan Studies in Contemporary Linguistics 55, nr 1 (26.03.2018): 53–87. http://dx.doi.org/10.1515/psicl-2019-0003.

Pełny tekst źródła

Streszczenie:

Abstract Stripping is a phenomenon whereby a full clause is coordinated with a phrase (XP) and an adverb, typically NEG(ation) (e.g. John read Hamlet but not Othello). As noted previously in the literature (e.g. Bosque 1984), while in English NEG must precede XP, Spanish allows the reverse order as well (XP-NEG). This paper examines these two strings (i.e. XP-NEG and NEG-XP) in Spanish and compares them with respect to a number of properties. The major goal of this paper is to show that, despite the appearances, the two strings constitute radically distinct phenomena. Analytically, I defend, in line with many others, that XP-NEG involves sentential coordination and clausal ellipsis (Depiante 2000; Vicente 2006, a.o.). With respect to NEG-XP, I contend that it involves constituent negation, constituent coordination and no ellipsis at all. This paper thus provides novel data and arguments which support the view originally proposed in Bosque (1984).

Style APA, Harvard, Vancouver, ISO itp.

18

Rana, MS, MM Rahman, UK Rima i NS Juyena. "General anaesthesia of indigenous pigs in Bangladesh". Bangladesh Veterinarian 30, nr 2 (6.03.2014): 46–53. http://dx.doi.org/10.3329/bvet.v30i2.18254.

Pełny tekst źródła

Streszczenie:

Anaesthetic trials were conducted with propofol (P), xylazine-propofol (XP), xylazine-ketamine (XK), xylazine-thiopentone (XT) in 16 healthy indigenous pigs. Respiration rate decreased significantly (P < 0.01) five minutes after induction, and during maximum depth of anaesthesia, and had not returned to control value after recovery from anaesthesia with all anaesthetic combinations. Heart rate with P increased significantly (P<0.01) five minutes after induction, whereas it decreased significantly (P < 0.01) with XP, XK and XT during anaesthesia and remained below the normal range after recovery from anaesthesia except after XP. In all anaesthetic sessions, rectal temperature decreased significantly (P < 0.01) in all stages of anaesthesia: after recovery the rectal temperature almost returned to control value in P and XP. Slight to moderate salivation was observed in all pigs with P and XP. It is suggested that P and XP combination seems to be suitable for general anaesthesia in pigs, but XP is more suitable. DOI: http://dx.doi.org/10.3329/bvet.v30i2.18254 Bangl. vet. 2013. Vol. 30, No. 2, 46-53

Style APA, Harvard, Vancouver, ISO itp.

19

Karentz, D., i J. E. Cleaver. "Repair-deficient xeroderma pigmentosum cells made UV light resistant by fusion with X-ray-inactivated Chinese hamster cells." Molecular and Cellular Biology 6, nr 10 (październik 1986): 3428–32. http://dx.doi.org/10.1128/mcb.6.10.3428.

Pełny tekst źródła

Streszczenie:

Xeroderma pigmentosum (XP) is an autosomal recessive human disease, characterized by an extreme sensitivity to sunlight, caused by the inability of cells to repair UV light-induced damage to DNA. Cell fusion was used to transfer fragments of Chinese hamster ovary (CHO) chromosomes into XP cells. The hybrid cells exhibited UV resistance and DNA repair characteristics comparable to those expressed by CHO cells, and their DNA had greater homology with CHO DNA than did the DNA from XP cells. Control experiments consisted of fusion of irradiated and unirradiated XP cells and repeated exposure of unfused XP cells to UV doses used for hybrid selection. These treatments did not result in an increase in UV resistance, repair capability, or homology with CHO DNA. The hybrid cell lines do not, therefore, appear to be XP revertants. The establishment of these stable hybrid cell lines is an initial step toward identifying and cloning CHO DNA repair genes that complement the XP defect in human cells. The method should also be applicable to cloning genes for other diseases, such as ataxia-telangiectasia and Fanconi's anemia.

Style APA, Harvard, Vancouver, ISO itp.

20

Karentz, D., i J. E. Cleaver. "Repair-deficient xeroderma pigmentosum cells made UV light resistant by fusion with X-ray-inactivated Chinese hamster cells". Molecular and Cellular Biology 6, nr 10 (październik 1986): 3428–32. http://dx.doi.org/10.1128/mcb.6.10.3428-3432.1986.

Pełny tekst źródła

Streszczenie:

Xeroderma pigmentosum (XP) is an autosomal recessive human disease, characterized by an extreme sensitivity to sunlight, caused by the inability of cells to repair UV light-induced damage to DNA. Cell fusion was used to transfer fragments of Chinese hamster ovary (CHO) chromosomes into XP cells. The hybrid cells exhibited UV resistance and DNA repair characteristics comparable to those expressed by CHO cells, and their DNA had greater homology with CHO DNA than did the DNA from XP cells. Control experiments consisted of fusion of irradiated and unirradiated XP cells and repeated exposure of unfused XP cells to UV doses used for hybrid selection. These treatments did not result in an increase in UV resistance, repair capability, or homology with CHO DNA. The hybrid cell lines do not, therefore, appear to be XP revertants. The establishment of these stable hybrid cell lines is an initial step toward identifying and cloning CHO DNA repair genes that complement the XP defect in human cells. The method should also be applicable to cloning genes for other diseases, such as ataxia-telangiectasia and Fanconi's anemia.

Style APA, Harvard, Vancouver, ISO itp.

21

Martens, M. C., L. Boeckmann i S. Emmert. "Genetisch bedingte Hauterkrankungen – Xeroderma pigmentosum und das CEDNIK-Syndrom". Aktuelle Dermatologie 46, nr 08/09 (20.08.2020): 375–78. http://dx.doi.org/10.1055/a-1148-3867.

Pełny tekst źródła

Streszczenie:

ZusammenfassungDie Rostocker Hautklinik ist Europäisches Referenznetzwerkzentrum für seltene Hauterkrankungen mit den besonderen Schwerpunkten Xeroderma pigmentosum und Ichthyosen. Diese Themen vertreten wir auch in der medizinischen Grundlagenforschung.Xeroderma pigmentosum (XP) ist eine seltene, autosomal-rezessive Erkrankung, die entsprechend der Gendefekte in 7 Komplementationsgruppen – XP-A bis XP-G sowie die sog. XP-Variante (XP-V) – eingeteilt wird. XP ist ein Nukleotid-Exzisions-Reparatur-Defektsyndrom und äußert sich v. a. durch vorzeitige Hautalterung und frühzeitige Entwicklung von Hauttumoren.Das seltene, neurokutane CEDNIK-Syndrom ist eine autosomal-rezessive Erkrankung, der eine Loss-of-Function-Mutation in SNAP29 zugrunde liegt. SNAP29 ist ein SNARE-Protein und an intrazellulären Membranfusionen beteiligt. CEDNIK ist ein Akronym für den mit dem Syndrom assoziierten Symptomkomplex aus zerebraler Dysgenese, Neuropathie, Ichthyose und Palmoplantarkeratosen. CEDNIK-Patienten weisen neben der Ichthyose zudem Gedeihstörungen, eine psychomotorische Retardierung und faziale Dysmorphien auf.

Style APA, Harvard, Vancouver, ISO itp.

22

Rothkopf, Michael. "An Algorithmic Approach for Lipid Metabolism and Management of Patients with Xanthelasma Palpebrarum (XP)". Current Developments in Nutrition 4, Supplement_2 (29.05.2020): 1140. http://dx.doi.org/10.1093/cdn/nzaa055_025.

Pełny tekst źródła

Streszczenie:

Abstract Objectives XP (flat, yellowish plaques around the eyes) is difficult to treat and often recurs. We describe an algorithmic approach to explore the lipid metabolism and management of XP. Methods A 64 yo female with hypothyroidism, obesity, and metabolic syndrome was successful with weight loss and glycemia but noted recurrence of XP after a surgical excision. Her lipid profile (on rosuvastatin) revealed: total cholesterol 150 mg/dL, LDL 54 mg/dL, triglycerides 74 mg/dL, HDL 81 mg/dL. Apolipoprotein (Apo) A1 was 213 mg/dL (nl female > 140). Apo B100 was 63 mg/dL (nl < 130). Lp(a) was 29 mg/dL (nl < 30). LDL particles were 958 nmol/L (nl < 1000). LDL particle size was 20.9 nm (nl > 20.5). Small dense LDL particles were 598 nmol/L (nl < 528). There was presence of serum campesterol (3.7 mg/L; nl 0–7.0) and sitosterol (2.1 mg/L; nl 0–5.0), but not desmosterol or lathosterol. Oral ezetimibe (EZ), 10 mg/day was administered. After 8 months of therapy, campesterol and sitosterol dropped significantly (campesterol: 2.1, - 44%; sitosterol: 1.3, - 39%). XP lesions resolved completely. Results We developed an algorithmic approach to XP management. The sequence is as follows: 1) examine standard lipid levels, 2) examine levels of pro-atherogenic particles, 3) explore net cholesterol tissue transport, 4) confirm hepatic cholesterol synthesis suppression, 5) examine plant sterols, 6) treat the abnormalities detected. In this example case phytosterols were responsible for XP recurrence. Sitosterol and campesterol should be minimally absorbed by the gut through the Nieman Pick C1 Like 1 (NPC1L1) sterol influx transporter and eliminated by the sterol efflux transporters, adenosine triphosphate-binding cassette (ABC) ABCG5/ABCG8. If phytosterols are retained in the body, they may predispose to resistant XP. An algorithmic approach to XP suggested that hyper-absorption of plant sterols by the NPC1L1 transporter was present. This was clinically confirmed because inhibition of NPC1L1 transport (by EZ) significantly reduced plant sterol levels. Plant sterols were also clinically confirmed as the cause of her XP, since their reduction and led to XP resolution. Conclusions We present an algorithmic approach to help detail the metabolic etiology of XP and direct its management. The example case demonstrates its value to reduce XP recurrence and resolve XP in selected cases. Funding Sources None.

Style APA, Harvard, Vancouver, ISO itp.

23

Alakshar, Asmaa, Abdul Rahman Mohammed Saleh i Mehmet Omer Gorduysus. "Debris and Smear Layer Removal from Oval Root Canals Comparing XP-Endo Finisher, EndoActivator, and Manual Irrigation: A SEM Evaluation". European Journal of Dentistry 14, nr 04 (10.08.2020): 626–33. http://dx.doi.org/10.1055/s-0040-1714762.

Pełny tekst źródła

Streszczenie:

Abstract Objective This study aimed to assess and compare XP-Endo Finisher (XP) cleaning efficiency with respect to the amount of remaining debris and smear layer versus Max-I-Probe needle (CI), EndoActivator device (EA), and combination of XP-Endo Finisher file with EndoActivator device (XP+EA) in oval root canals. Materials and Methods This in vitro study was performed on 36 extracted single root/canal mandibular premolars. Radiographic images were taken in buccolingual and mesiodistal projections to evaluate the shape of the root canal and determine whether it met exclusion criteria. All teeth were decoronated and prepared using Reciproc (R40). The samples were divided randomly into four groups: CI, EA, XP, and XP + EA. The root canals were irrigated with 5 mL of 17% EDTA and 2.5% NaOCl, respectively. Apart from the CI group, both solutions were activated by using the tested techniques for 1 minute.The teeth were split longitudinally, and the best visible identified sections of the roots were used as the representing samples for scanning electron microscope (SEM) evaluation. Each half was divided into the following three parts: 1 mm from the anatomic apex and a standardized photomicrograph with 500x and 1500x magnifications for debris and smear layer were obtained. A five-grade scoring system was utilized to quantify the results at the coronal, middle, and apical regions. Statistical analysis was performed by using the Kruskal–Wallis and Mann–Whitney U tests. Results Group differences in debris and smear layer scores were found statistically significant for all locations as well as for overall assessment, except for the coronal third. Intragroup comparison of debris and smear layer in CI, EA, and XP had the minimum score at the middle third, with no significant difference compared with the coronal and apical thirds. XP + EA had less debris and smear layer score at the coronal third, significantly different from apical third.CI and EA had less debris and smear layer compared with XP and XP + EA at all locations with a significant difference at the middle and apical third (p < 0.05). Conclusion EA and CI showed less debris and smear layer than XP and XP + EA in the middle and apical third. The use of the XP in conjunction with the present irrigation protocol failed to have debris-free dentin surface in the apical portion of most of the root canals.

Style APA, Harvard, Vancouver, ISO itp.

24

Sugimoto, Naotoshi, Tetsuhiro Yoshinami, Sachiko Yamamoto, Toshinari Yagi i Fumio Imamura. "Does capecitabine plus cisplatin (XP) give advanced or recurrent gastric cancer (AGC) patients higher early tumor shrinkage (ETS) rate than S1 plus cisplatin (SP) with safety?" Journal of Clinical Oncology 33, nr 3_suppl (20.01.2015): 172. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.172.

Pełny tekst źródła

Streszczenie:

172 Background: Capecitabine plus cisplatin (XP) is defined as the platform regimen in many global trials (ex: ToGA, AVAGAST) for AGC in first-line setting. But in the Japanese Gastric Cancer Treatment Guideline (4th edition), S-1 plus cisplatin (SP) is mentioned the standard (recommendation 1), XP is considered as recommendation 2. Few reports were existed about the comparison between XP and SP. So we retrospectively compared the efficacy and toxicity of XP and SP for patients with AGC in our hospital. Methods: The selection criteria were pathologically proven AGC (HER2 negative or unknown); no previous chemotherapy; performance status 0-2; able to oral intake; and adequate organ functions. The patients in XP group, capecitabine 1,000mg/m2 was given orally twice daily for 14days followed by a 7-day rest; cisplatin 80mg/m2 on day1 was given by intravenous infusion. In SP group, S1 40mg/m2 was given orally twice daily for 21 days followed by a 14-day rest and cisplatin 60mg/m2 intravenous infusion on day8. Results: The analysis covered 115 patients over the period from May 2008 to June 2014. The median age was 64 years (range 22-81); 76 males and 39 females; PS 0/1/2 score 85/29/1; 31 patients were treated XP and 84 patients were treated SP. Progression-free survival and overall survival were 6.6 and 16.4 months with XP and 6.1 and 13.3 months with SP (no significant difference). The response rates were XP/SP 61%/50%. The ETS (over 20% tumor shrinkage in 6-8weeks) rate were 83% in XP and 61% in SP (p=0.09). The rate of grade 3-4 toxicity in XP/SP were; neutropenia 23%/15%, anemia 16%/20%, nausea 0%/3%, anorexia 3%/ 8%, fatigue 0%/ 4%, hyponatremia 3%/ 0%. There was no treatment death in both groups. Conclusions: It is suggested that XP give AGC patients high ETS rate with safety.

Style APA, Harvard, Vancouver, ISO itp.

25

Takeno, Atsushi, Youichi Makari, Shunji Endo, Jin Matsuyama, Ryohei Kawabata, Naotoshi Sugimoto, Hirokazu Taniguchi i in. "Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with tri-weekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 negative advanced gastric cancer (AGC): OGSG 1105 HERBIS-4A trial." Journal of Clinical Oncology 36, nr 4_suppl (1.02.2018): 102. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.102.

Pełny tekst źródła

Streszczenie:

102 Background: This phase II study aimed to investigate the safety and efficacy of XP compared to SP in the first-line treatment of HER2 negative AGC. Methods: Patients were randomly assigned to receive either SP (S-1 at 40–60 mg twice daily for 21 days plus cisplatin at 60 mg/ m2 on day 8, every 5 weeks) or XP (capecitabine 1,000 mg/m2 twice daily for 14 days plus cisplatin 80 mg/m2 on day 1, every 3 weeks). Primary endpoint was response rate (RR), and secondary endpoints were progression-free survival (PFS), overall survival (OS), time to treatment failure (TTF), and adverse events. Results: 84 eligible patients were randomly assigned to receive SP ( N = 41) or XP ( N = 43). No statistical difference was observed in overall RR between the SP and XP groups [51.2% (95% CI, 35.1% to 67.1%) vs. 53.5% (95% CI, 37.7% to 68.8%), P = 1.000]. Despite not significant, however, SP vs. XP showed a trend toward better PFS [median, 5.9 months vs. 4.1 months; hazard ratio (HR), 0.763; 95% CI, 0.462 to 1.259; P = .284] and OS (median, 13.5 months vs. 10.0 months; HR, 0.776; 95% CI, 0.485 to 1.244; P = .290). This trend in the SP vs. XP comparison was more pronounced in TTF (median, 4.5 months vs. 3.1 months; HR, 0.651; 95% CI, 0.421 to 1.006; P = .052). Common grade 3 to 4 hematological toxicities were neutropenia and anemia (SP group, 23% and 23%; XP group, 35% and 28%). Grade 3-4 anorexia and hyponatremia were more frequently seen in the XP group (31% and 16%) compared to the SP group (13% and 5%). Treatment-related deaths occurred in one patient (2.3%) in the XP group. Conclusions: XP failed to demonstrate the superior efficacy over SP. Higher incidence of severe toxicities by XP suggests SP as the standard 1st line chemotherapy for HER2 negative AGC in Japan. Clinical trial information: UMIN000006755.

Style APA, Harvard, Vancouver, ISO itp.

26

Bahrudin, Ida Aryanie, Rafizah Mohd Hanifa, Mohd Ezree Abdullah i Muhammad Firdaus Kamarudin. "Adapting eXtreme Programming Approach in Developing Electronic Document Online System (eDoc)". Applied Mechanics and Materials 321-324 (czerwiec 2013): 2938–41. http://dx.doi.org/10.4028/www.scientific.net/amm.321-324.2938.

Pełny tekst źródła

Streszczenie:

eXtreme Programming (XP) is one of new discipline of software development methodology on values of simplicity, communication, feedback and also courage. XP is an explorative and agile development method that seeks to satisfy the customer through early and continuous delivery of valuable software. XP software development process starts with planning, and all iterations consist of four basic phases in its life cycle: designing, coding, testing, and listening. This paper tends to report the experience in adapting XP in developing electronic document online system for the use of Centre for Diploma Studies, Universiti Tun Hussein Onn Malaysia (eDoc). The project under study is a system that is use to store office documents such as letter in an online database. The objective of this paper is to discuss the XP practices that had been choosed and also the lesson learnt by practising XP in developing eDoc.

Style APA, Harvard, Vancouver, ISO itp.

27

Gengler, Barbara. "XP a National Threat?" Network Security 2001, nr 11 (listopad 2001): 5. http://dx.doi.org/10.1016/s1353-4858(01)01111-4.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

28

J.-M.M. "XP Centaur en majesté". Revue Francophone des Laboratoires 2007, nr 388 (styczeń 2007): 10. http://dx.doi.org/10.1016/s1773-035x(07)80003-7.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

29

Schwarz, Diemo, i Etienne Brunet. "theconcatenator: Placard XP edit". Leonardo Music Journal 18 (grudzień 2008): 89–90. http://dx.doi.org/10.1162/lmj.2008.18.89b.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

30

Reifer, D. J. "XP and the CMM". IEEE Software 20, nr 3 (maj 2003): 14–15. http://dx.doi.org/10.1109/ms.2003.1196314.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

31

Torre, Alberto C. de la. "The ubiquitous XP commutator". European Journal of Physics 27, nr 2 (3.01.2006): 225–30. http://dx.doi.org/10.1088/0143-0807/27/2/005.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

32

Fraser, Steven, i Giancarlo Succi. "XP requirement negotiation workshop". ACM SIGAPP Applied Computing Review 10, nr 1 (kwiecień 2002): 26–31. http://dx.doi.org/10.1145/568235.568239.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

33

Yu, Jeong Il, Hee Chul Park, Jeeyun Lee, Changhoon Choi, Won Ki Kang, Se Hoon Park, Seung Tae Kim i in. "Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer". Cancers 12, nr 4 (10.04.2020): 943. http://dx.doi.org/10.3390/cancers12040943.

Pełny tekst źródła

Streszczenie:

Background: The purpose of this study was to evaluate the clinical outcomes following postoperative chemotherapy (XP) versus chemoradiotherapy (XP-RT) according to mesenchymal subtype based on RNA sequencing in gastric cancer (GC) in a cohort of the Adjuvant chemoRadioTherapy In Stomach Tumor (ARTIST) trial. Methods: Of the 458 patients enrolled in the ARTIST trial, formalin-fixed, paraffin-embedded (FFPE) specimens were available from 106 (23.1%) patients for RNA analysis. The mesenchymal subtype was classified according to a previously reported 71-gene MSS/EMT signature using the NanoString assay. Results: Of the 106 patients analyzed (50 in XP arm, 56 in XP-RT arm), 36 (34.0%) patients were categorized as mesenchymal subtype by NanoString assay. Recurrence-free survival (RFS, p = 0.009, hazard ratio (HR) = 2.11, 95% confidence interval (CI): 1.21–3.70) and overall survival (OS, p = 0.003, HR = 2.28, 95% CI: 1.31–3.96) were significantly lower in the mesenchymal subtype than in the non-mesenchymal subtype. In terms of post-operative radiotherapy (RT), mesenchymal subtype was not an independent variable to predict RFS or OS regardless to the assigned arm (XP with or without RT) in this patient cohort. However, there was a trend in the adjuvant XP arm, which showed higher OS than the XP-RT arm for the mesenchymal subtype and lower OS than the XP-RT arm for the non-mesenchymal subtype. Conclusions: We could not determine any significant differences between the mesenchymal and non-mesenchymal subtypes with respect to the effects of adjuvant XP with or without RT in gastric cancer following curative surgery.

Style APA, Harvard, Vancouver, ISO itp.

34

Poulin, Yves, Robert Bissonnette, Christina Juneau, Kim Cantin, Rejean Drouin i Patrice E. Poubelle. "XP-828L in the Treatment of Mild to Moderate Psoriasis: Randomized, Double-Blind, Placebo-Controlled Study". Journal of Cutaneous Medicine and Surgery 10, nr 5 (wrzesień 2006): 241–48. http://dx.doi.org/10.2310/7750.2006.00049.

Pełny tekst źródła

Streszczenie:

Background: XP-828L, a protein extract obtained from sweet whey, has demonstrated potential benefit for the treatment of mild to moderate psoriasis in an open-label study. Objective: To study in a randomized, double-blind, placebo-controlled study the safety and efficacy of XP-828L in the treatment of mild to moderate psoriasis. Design: XP-828L 5 g/d (group A, n = 42) or placebo (group B, n = 42) was given orally for 56 days followed by XP-828L 5 g/d in group A and by XP-828L 10 g/d in group B for an additional 56 days. Results: Patients receiving XP-828L 5 g/d for 56 days had an improved Physician's Global Assessment (PGA) score compared with patients under placebo ( p < .05). Considering the data of group A only, the PGA score improved from day 1 to day 56 ( p < .01); the Psoriasis Area and Severity Index score improved as well, but to a lesser extent ( p < .05). Conclusion: Oral administration of 5 g/d XP-828L compared with a placebo significantly improved the PGA score of patients with mild to moderate psoriasis.

Style APA, Harvard, Vancouver, ISO itp.

35

Beroual, Nabil, i Ahmed Bendjeddou. "On a Predator–Prey System with Holling Functional Response: xp/(a + xp)". National Academy Science Letters 39, nr 1 (12.10.2015): 43–46. http://dx.doi.org/10.1007/s40009-015-0400-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

36

Yang, Tianyu, Can Ding, Richard W. Ziolkowski i Y. Jay Guo. "A Terahertz (THz) Single-Polarization-Single-Mode (SPSM) Photonic Crystal Fiber (PCF)". Materials 12, nr 15 (31.07.2019): 2442. http://dx.doi.org/10.3390/ma12152442.

Pełny tekst źródła

Streszczenie:

This paper presents a novel approach to attain a single-polarization-single-mode (SPSM) photonic crystal fiber (PCF) in the terahertz (THz) regime. An initial circular hole PCF design is modified by introducing asymmetry in the first ring of six air holes in the cladding, i.e., epsilon-near-zero (ENZ) material is introduced into only four of those air holes and the other two remain air-filled but have different diameters. The resulting fundamental X-polarized (XP) and Y-polarized (YP) modes have distinctly different electric field distributions. The asymmetry is arranged so that the YP mode has a much larger amount of the field distributed in the ENZ material than the XP mode. Since the ENZ material is very lossy, the YP mode suffers a much higher loss than the XP mode. Consequently, after a short propagation distance, the loss difference (LD) between the XP and YP modes will be large enough that only the XP mode still realistically exists in the PCF. To further enhance the outcome, gain material is introduced into the core area to increase the LDs between the wanted XP mode and any unwanted higher order (HO) modes, as well as to compensate for the XP mode loss without affecting the LD between the XP and YP modes. The optimized PCF exhibits LDs between the desired XP mode and all other modes greater than 8.0 dB/cm across a wide frequency range of 0.312 THz. Consequently, the reported PCF only needs a length of 2.5 cm to attain an SPSM result, with the unwanted modes being more than 20 dB smaller than the wanted mode over the entire operational band.

Style APA, Harvard, Vancouver, ISO itp.

37

Lee, Ji Eun, Myung Ah Lee, Tae Ho Hong, In Seok Lee i Young Kyoung You. "Comparison of the efficacy between the gemcitabine/cisplatin (GP) and capecitabine/cisplatin (XP) for the advanced biliary tract cancer: Retrospective analysis in a single institution." Journal of Clinical Oncology 30, nr 4_suppl (1.02.2012): 365. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.365.

Pełny tekst źródła

Streszczenie:

365 Background: Bile duct cancers (BTC) are known to be the chemotherapy resistant cancer, and more common in old-age group. Gemcitabine and cisplatin (GP) has been widely used as first line treatment for unresectable BTC. Capecitabine and cisplatin (XP) combination chemotherapy has been also used as another option treatment. We retrospectively compared the efficacy of GP and XP for advanced BTC. Methods: Between Jan, 2009 and Jun, 2011, Fifty five patients who were diagnosed with unresectable BTC at Seoul St. Mary’s hospital were enrolled for analysis of the efficacy in the present study. All the patients had recurrent disease or metastatic cancer, confirmed by histologically adenocarcima. In GP group, gemcitabine was given with 1,000mg/m2, I.V for 30min on d1 and d8, and cisplatin was injected with 75mg/m2, d1, repeated every 21 days. In XP group, capecitabine was administered by orally 2,000mg/m2, divided dose d1-14, and cisplatin was administerd with 75mg/m2, d1, repeated every 21 days. Response evaluation with CT scan was taken after 2 cycles. Results: Of the 55 patients enrolled, 28 patients were treated with GP and 27 patients were treated with XP. Median age was 69 years old in GP, 65 years old in XP. Median number of cycle was 2.5 in both groups. There was no difference in patients’ characteristics between two groups in terms of sex, age, number of cycle and disease status. In analysis of the response rate, Partial response rate was 38.5% in XP, and 7.1% in GP, and stable disease was achieved in 23.1% in XP, 42.9% in GP (p=0.004). Median time to progression was 2.0 mon in GP, and 4 mon in XP (P=0.147). However, median survival time was 6 months vs. 4. 3months in GP and XP, respectively (p=0.510). There was no difference in toxicity between two groups. Conclusions: GP and XP showed similar clinical outcome, such as TTP or OS, although XP had significantly better response rate. These two regimens had modest activity, but not effective in terms of TTP or OS. Median number of cycles was only 2.5 in both groups because most patients were over 65 years old, and had poor performance status. Development of new effective regimens in advanced BTC should be warranted.

Style APA, Harvard, Vancouver, ISO itp.

38

De Braud, Filippo G., i Wentao Jason Wu. "A dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of mTORC1/2 inhibitor XP-105 (BI 860585) as monotherapy and in combination with exemestane or paclitaxel in patients (pts) with advanced solid tumors." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): 3127. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.3127.

Pełny tekst źródła

Streszczenie:

3127 Background: Resistance to mTORC1 inhibition may develop through feedback loop leading to upregulation of mTORC2. XP-105, also known as BI 860585, is a potent dual mTORC1/2 inhibitor designed to overcome such resistance. This Phase 1 trial (NCT01938846) was performed to determine the MTD and activity of XP-105 alone or in combination with exemestane or paclitaxel in pts with advanced solid tumors. Methods: A 3+3 escalation design was used; Pts received XP-105 (5–300 mg/day) monotherapy or (40–220 mg/day) combined with fixed-dose exemestane 25 mg/day, or 80–160 mg/day combined with paclitaxel 60 or 80 mg/m2/week. A reduction of pAKT/total AKT ratio was used as a PD marker of target inhibition. Results: 90 pts were treated (41 with monotherapy, 25 and 24 in combination with exemestane, or paclitaxel respectively). XP-105 MTD was defined as 220 mg daily for monotherapy, and 160mg daily with exemestane 25 mg/d or paclitaxel 80 mg/m2/week. In the monotherapy arm, stable disease (SD) was reported in 8 pts (20%), with a median duration of 11 months. In the exemestane combination arm, 4 (16%) partial responses (PR) were reported. In the paclitaxel combination arm, 1 complete response (CR) and 4 PRs were reported (OR rate 21%). Disease control rate (CR/PR/SD) was 20%, 28%, and 58% in the monotherapy, XP-105/exemestane, and XP-105/paclitaxel arms, respectively. A sustained reduction in pAKT/total AKT to < 50% of baseline levels was observed with XP-105 ≥120mg daily. Overall, XP-105 was well tolerated; in the XP-105/paclitaxel combination the most frequent drug-related AEs were diarrhea and fatigue (58.3% each), hyperglycaemia (54.2%), anaemia (50%). Grade ≥3 AEs were hyperglycaemia, fatigue, diarrhea, anaemia, leukopenia. No PK interaction was observed. Conclusions: The MTD for XP-105 monotherapy and in combination with exemestane or paclitaxel was defined as 220 mg and 160mg once daily, respectively. Combination regimens showed higher activity as compared to monotherapy with durable OR in about 20% of pts. The observed safety profile of XP-105 compared favorably to those reported from other mTOR inhibitors. Clinical trial information: NCT01938846.

Style APA, Harvard, Vancouver, ISO itp.

39

Ben Rekaya, Mariem, Nadia Laroussi, Olfa Messaoud, Mariem Jones, Manel Jerbi, Chokri Naouali, Yosra Bouyacoub i in. "A Founder Large Deletion Mutation in Xeroderma Pigmentosum-Variant Form in Tunisia: Implication for Molecular Diagnosis and Therapy". BioMed Research International 2014 (2014): 1–8. http://dx.doi.org/10.1155/2014/256245.

Pełny tekst źródła

Streszczenie:

Xeroderma pigmentosum Variant (XP-V) form is characterized by a late onset of skin symptoms. Our aim is the clinical and genetic investigations of XP-V Tunisian patients in order to develop a simple tool for early diagnosis. We investigated 16 suspected XP patients belonging to ten consanguineous families. Analysis of thePOLHgene was performed by linkage analysis, long range PCR, and sequencing. Genetic analysis showed linkage to thePOLHgene with a founder haplotype in all affected patients. Long range PCR of exon 9 to exon 11 showed a 3926 bp deletion compared to control individuals. Sequence analysis demonstrates that this deletion has occurred between two Alu-Sq2 repetitive sequences in the same orientation, respectively, in introns 9 and 10. We suggest that this mutationPOLHNG_009252.1: g.36847_40771del3925 is caused by an equal crossover event that occurred between two homologous chromosomes at meiosis. These results allowed us to develop a simple test based on a simple PCR in order to screen suspected XP-V patients. In Tunisia, the prevalence of XP-V group seems to be underestimated and clinical diagnosis is usually later. Cascade screening of this founder mutation by PCR in regions with high frequency of XP provides a rapid and cost-effective tool for early diagnosis of XP-V in Tunisia and North Africa.

Style APA, Harvard, Vancouver, ISO itp.

40

Krasikova, Yuliya, Nadejda Rechkunova i Olga Lavrik. "Nucleotide Excision Repair: From Molecular Defects to Neurological Abnormalities". International Journal of Molecular Sciences 22, nr 12 (9.06.2021): 6220. http://dx.doi.org/10.3390/ijms22126220.

Pełny tekst źródła

Streszczenie:

Nucleotide excision repair (NER) is the most versatile DNA repair pathway, which can remove diverse bulky DNA lesions destabilizing a DNA duplex. NER defects cause several autosomal recessive genetic disorders. Xeroderma pigmentosum (XP) is one of the NER-associated syndromes characterized by low efficiency of the removal of bulky DNA adducts generated by ultraviolet radiation. XP patients have extremely high ultraviolet-light sensitivity of sun-exposed tissues, often resulting in multiple skin and eye cancers. Some XP patients develop characteristic neurodegeneration that is believed to derive from their inability to repair neuronal DNA damaged by endogenous metabolites. A specific class of oxidatively induced DNA lesions, 8,5′-cyclopurine-2′-deoxynucleosides, is considered endogenous DNA lesions mainly responsible for neurological problems in XP. Growing evidence suggests that XP is accompanied by defective mitophagy, as in primary mitochondrial disorders. Moreover, NER pathway is absent in mitochondria, implying that the mitochondrial dysfunction is secondary to nuclear NER defects. In this review, we discuss the current understanding of the NER molecular mechanism and focuses on the NER linkage with the neurological degeneration in patients with XP. We also present recent research advances regarding NER involvement in oxidative DNA lesion repair. Finally, we highlight how mitochondrial dysfunction may be associated with XP.

Style APA, Harvard, Vancouver, ISO itp.

41

Poddar, Rakshapada, Subhradeep Chakraborty i Sudipta Chattopadhyay. "Improved Cross Polarization and Broad Impedance Bandwidth from Simple Single Element Shorted Rectangular Microstrip Patch: Theory and Experiment". Frequenz 70, nr 1-2 (1.01.2016): 1–9. http://dx.doi.org/10.1515/freq-2015-0105.

Pełny tekst źródła

Streszczenie:

AbstractA simple, compact and single element rectangular microstrip antenna with three pairs of shorting plates has been proposed and investigated experimentally for broad impedance bandwidth and improved cross polarized (XP) radiation compared to maximum co-polarized (CO) gain without affecting the co-polarized radiation pattern. Around 25–40 dB isolation between copolarized radiation to cross polarized radiation (CO-XP isolation) along with 1.32 GHz impedance bandwidth is achieved with the proposed structure. The present structure is very simple and easy to manufacture and provides high CO-XP isolation over entire angular range around the broadside direction. Moreover, the present structure is free from back radiation in terms of XP fields. The present investigation provides an insightful, visualization-based understanding of concurrent improvement in impedance bandwidth and the XP radiation characteristics with the present structure.

Style APA, Harvard, Vancouver, ISO itp.

42

García-García, J. I., D. Marín-Aragón i A. Vigneron-Tenorio. "Union of Sets of Lengths of Numerical Semigroups". Mathematics 8, nr 10 (15.10.2020): 1789. http://dx.doi.org/10.3390/math8101789.

Pełny tekst źródła

Streszczenie:

Let S=⟨a1,…,ap⟩ be a numerical semigroup, let s∈S and let Z(s) be its set of factorizations. The set of lengths is denoted by L(s)={L(x1,⋯,xp)∣(x1,⋯,xp)∈Z(s)}, where L(x1,⋯,xp)=x1+⋯+xp. The following sets can then be defined: W(n)={s∈S∣∃x∈Z(s)suchthatL(x)=n}, ν(n)=⋃s∈W(n)L(s)={l1<l2<⋯<lr} and Δν(n)={l2−l1,…,lr−lr−1}. In this paper, we prove that the function Δν:N→P(N) is almost periodic with period lcm(a1,ap).

Style APA, Harvard, Vancouver, ISO itp.

43

Mulyantari, Kadek, Aryati . i M. Y. Probohoesodo. "PENEMUAN (DETEKSI) ANTIBODI UNTUK ANTIGEN TUBERKULOSIS MENGGUNAKAN METODE IMUNOKROMATOGRAFI DI PENDERITA TUBERKULOSIS PARU". INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY 14, nr 3 (16.03.2018): 127. http://dx.doi.org/10.24293/ijcpml.v14i3.938.

Pełny tekst źródła

Streszczenie:

The gold standard for TB still has some drawbacks, such as a long duration for culture examination and the rolated facilities are notalways available in all laboratories. One of methods in diagnosing tuberculosis infection is by immunochromatography (ICT). MYCOTECTB xp (recombinant) is one of serologic tests using immunochromatography principle. MYCOTEC TB xp uses recombinant antigens 38kDa, 16 kDa, 6 kDa and Early Secreted Antigen Target (ESAT-6). This method is expected so far diagnose TB in a short time and has ahigh accuracy. Evaluating the immunochromatography method in detecting antibody by tuberculosis antigen in lung TB patients as willthose with nonTB lung disease (lung tumor, bronchial asthma, pneumonia, chronic obstructive lungdisease). Serum samples of 30 TBpatients in BP4/Karang Tembok Hospital Surabaya and 30 non TB patients in the Dr. Soetomo Hospital Surabaya. Detection of antibodyto tuberculosis antigen was done with MYCOTEC TB xp. In this study found is prond 30 TB patients using MYCOTEC TB xp was positivein 23 samples and negative in 7 samples. From the 30 nonTB patients MYCOTEC TB xp was positive in 4 samples and negative in 26samples. It can be uncloaded so far that the diagnostic sensitivity of MYCOTEC TB xp was 76.7% (23/30) and diagnostic specificity was86.7% (26/30). MYCOTEC TB xp has an intermediate diagnostic sensitivity of 76.7% and a high diagnostic specificity of 86.7%.

Style APA, Harvard, Vancouver, ISO itp.

44

Kang, Y., W. K. Kang, D. B. Shin, J. Chen, J. Xiong, J. Wang, M. Lichinitser, M. Philco, T. Suarez i J. Santamaria. "Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results". Journal of Clinical Oncology 24, nr 18_suppl (20.06.2006): LBA4018. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.lba4018.

Pełny tekst źródła

Streszczenie:

LBA4018 Background: The oral fluoropyrimidine capecitabine has proven efficacy and safety in colorectal and breast cancer. Phase II data in AGC suggested that XP would show comparable efficacy to a standard FP regimen, with potential safety and convenience advantages. This phase III study evaluated XP vs. FP in first-line AGC. Methods: Pts with previously untreated measurable AGC received either oral capecitabine (1000mg/m2 bid d1–14) + cisplatin (80mg/m2 i.v. d1) q3w (XP arm) or 5-FU (800mg/m2/d continuous infusion, d1–5) + cisplatin (80mg/m2 i.v. d1) q3w (FP arm). XP requires 1 day per 3 weeks in hospital; FP requires 5 days. Pts were treated until disease progression or unacceptable toxicity. Primary endpoint: non-inferiority (NI) in progression-free survival (PFS), defined as upper limit of 95% CI of hazard ratio (HR) <1.4 (first test) and <1.25 (second test). Results: From Apr 03 to Jan 05, 316 pts were enrolled in 46 centers/13 countries. Arms were well balanced: median age (years, range) XP (56, 26–74), FP (56, 22–73); median Karnofsky PS 80 (range 70–100) in both arms; male/female (%): XP (64/36) FP (69/31). Median no. of cycles was 5 (XP and FP). Median follow-up is 22.1 months. Primary endpoint was met: HR 0.81 (95% CI 0.63–1.04). XP was superior to FP in terms of overall response rate (ORR, RECIST). Efficacy is presented in the table. Most common treatment-related grade 3/4 adverse events (XP vs. FP) were: neutropenia (16 vs. 19%), vomiting (7 vs. 9%), stomatitis (2 vs. 7%), diarrhea (5 vs. 5%), and anemia (5 vs. 3%). Other grade 3/4 events occurred in <5% of pts. The rate of all-grade hand-foot syndrome was low (22 vs. 4%). Conclusions: XP showed highly significant non-inferiority for PFS and significant superiority for ORR vs. FP with similar safety. These findings suggest that capecitabine should become the fluoropyrimidine of choice for AGC, given the efficacy, reduced hospitalization time and simplified regimen. No significant financial relationships to disclose. [Table: see text]

Style APA, Harvard, Vancouver, ISO itp.

45

Armelini, Melissa G., Keronninn M. Lima-Bessa, Maria Carolina N. Marchetto, Alysson R. Muotri, Vanessa Chiganças, Ricardo A. Leite, Helotonio Carvalho i Carlos F. M. Menck. "Exploring DNA damage responses in human cells with recombinant adenoviral vectors". Human & Experimental Toxicology 26, nr 11 (listopad 2007): 899–906. http://dx.doi.org/10.1177/0960327107083556.

Pełny tekst źródła

Streszczenie:

Recombinant adenoviral vectors provide efficient means for gene transduction in mammalian cells in vitro and in vivo. We are currently using these vectors to transduce DNA repair genes into repair deficient cells, derived from xeroderma pigmentosum (XP) patients. XP is an autosomal syndrome characterized by a high frequency of skin tumors, especially in areas exposed to sunlight, and, occasionally, developmental and neurological abnormalities. XP cells are deficient in nucleotide excision repair (affecting one of the seven known XP genes, xpa to xpg) or in DNA replication of DNA lesions (affecting DNA polymerase eta, xpv). The adenovirus approach allows the investigation of different consequences of DNA lesions in cell genomes. Adenoviral vectors carrying several xp and photolyases genes have been constructed and successfully tested in cell culture systems and in vivo directly in the skin of knockout model mice. This review summarizes these recent data and proposes the use of recombinant adenoviruses as tools to investigate the mechanisms that provide protection against DNA damage in human cells, as well as to better understand the higher predisposition of XP patients to cancer. Human & Experimental Toxicology (2007) 26, 899—906

Style APA, Harvard, Vancouver, ISO itp.

46

Beal Partyka, Raul, Jeferson Lana i Rosilene Marcon. "A XP e o Itaú Unibanco: dos Produtos de Investimento a Desbancarização". Administração: Ensino e Pesquisa 21, nr 2 (1.05.2020): 214–38. http://dx.doi.org/10.13058/raep.2020.v21n2.1749.

Pełny tekst źródła

Streszczenie:

Este caso para ensino apresenta a narrativa da aquisição da XP Investimentos pelo Itaú Unibanco. O banco ofertou a compra da XP Investimentos. Este movimento ocorreu pouco antes da corretora pedir o registro para realizar seu IPO (Oferta Inicial de Ações, sigla em inglês) na bolsa de valores brasileira (B3). O objetivo do estudo é impulsionar as discussões da operação de aquisição para os temas de estrutura de governança e a teoria dos custos de transação em meio a inovação tecnológica no mercado financeiro brasileiro. Pelo lado da XP o plano era claro: em uma tacada só, ficar com o ativo e eliminar um concorrente, podendo agora não apenas sonhar em ser o maior grupo de investimentos do Brasil. Já para o Itaú Unibanco – maior player do mercado - passa a ter a carteira da XP pronta e elimina um concorrente que lhe tirava market share. O caso indica discussões sobre a lógica por trás da aquisição da XP pelo Itaú Unibanco. Ainda, permite indagar se não seria capaz o maior banco do Brasil, desenvolver tais capacidades adquiridas da corretora, além de questionar se as capacidades internalizadas da XP são tão valiosas a ponto de tamanho investimento.

Style APA, Harvard, Vancouver, ISO itp.

47

Drouin, Réjean, Éric Lamiot, Kim Cantin, Sylvie F. Gauthier, Yves Pouliot, Patrice E. Poubelle i Christina Juneau. "XP-828L (Dermylex), a new whey protein extract with potential benefit for mild to moderate psoriasisThis article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products." Canadian Journal of Physiology and Pharmacology 85, nr 9 (wrzesień 2007): 943–51. http://dx.doi.org/10.1139/y07-084.

Pełny tekst źródła

Streszczenie:

Natural health products (NHPs) or complementary and alternative medicine (CAM) are commonly used to prevent disorders or support the usual treatments of many diseases. XP-828L, a whey protein extract, has demonstrated potential benefits for the treatment of mild to moderate psoriasis. The aim of this study was to analyze further clinical data that demonstrated the clinical benefits and safety of the XP-828L in patients with psoriasis and the potential mechanism of action of this product in vitro. Oral administration (2.5 g, twice a day, over 112 days) of XP-828L in 42 human subjects with mild to moderate psoriasis improved their PGA scores (physician’s global assessment). Moreover, no significant changes in haematology or hepatic and renal parameters were observed throughout the study period, indicating the safety of the product. In vitro experiments showed that XP-828L decreased the proliferation of concanavalin A (ConA)-stimulated murine splenocytes and their production of interleukin (IL)-2 and interferon (IFN)-γ. Although the in vivo mechanism of action of XP-828L remains unknown, XP-828L represents an NHP to be used as an alternative or concomitant treatment for mild to moderate psoriasis and potentially for other immune-mediated diseases.

Style APA, Harvard, Vancouver, ISO itp.

48

Truckenbrodt, Hubert. "On the Relation between Syntactic Phrases and Phonological Phrases". Linguistic Inquiry 30, nr 2 (kwiecień 1999): 219–55. http://dx.doi.org/10.1162/002438999554048.

Pełny tekst źródła

Streszczenie:

This article argues that the relation between syntactic XPs and phonological phrases is subject to a constraint, WRAP-XP, that demands that each XP be contained in a phonological phrase. WRAP-XP is argued to interact with the constraints on edge alignment proposed by Selkirk (1986, 1995), with a constraint against recursive structure, and with a constraint aligning an edge of a focus with a phonological phrase. WRAP-XP is intended to replace, and improve on, an earlier proposal by Hale and Selkirk (1987) to the effect that lexical government plays a role in the syntax-prosody mapping. The languages discussed in more detail are Tohono O'odham, Kimatuumbi, and Chicheŵa.

Style APA, Harvard, Vancouver, ISO itp.

49

Onishi, Masazumi, Kanako Tsunoda, Fumihiko Maeda, Shinichi Moriwaki i Hiroo Amano. "Angiosarcoma of the Auricle in a Patient with Xeroderma Pigmentosum Variant". Case Reports in Dermatology 12, nr 2 (18.08.2020): 144–49. http://dx.doi.org/10.1159/000508884.

Pełny tekst źródła

Streszczenie:

Xeroderma pigmentosum (XP) is an inherited autosomal recessive disorder characterized by photosensitivity and an increased risk of developing multiple skin neoplasms at sites exposed to the sun. We report a 73-year-old Japanese man with angiosarcoma of the auricle and an XP-variant, which is a very rare condition. In this case, long-term physical stimulation due to auricular deformation after surgery may have been the cause. Angiosarcoma associated with XP has a better prognosis than common angiosarcoma, perhaps because of the smaller tumor size. As XP patients are at high risk of skin neoplasms, they consult dermatologists regularly, and therefore skin tumors are likely to be detected early.

Style APA, Harvard, Vancouver, ISO itp.

50

Lueck, H., G. V. Minckwitz, A. Du Bois, I. Schrader, J. Huober, V. Heilmann, M. Beckmann i in. "Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): A prospective, randomized multicentre phase III study of the AGO breast cancer study group". Journal of Clinical Oncology 24, nr 18_suppl (20.06.2006): 517. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.517.

Pełny tekst źródła

Streszczenie:

517 Background: Anthracyline-taxane combinations have the highest response rates in high risk MBC. Recently, anthracyclines and taxanes have become standards for adjuvant breast cancer chemotherapy. The addition of capecitabine to docetaxel improved overall survival in MBC. This regime was associated with a high rate of side effects (actually FN was not different from Taxotere mono - it was more the addition of cape AEs to Taxotere AEs). Earlier phase II studies with XP are able to show efficacy with better tolerability including less febrile neutropenia. Methods: Our aim was to show non-inferiority of XP to EP. The primary endpoint was progression-free survival (PFS). Secondary endpoints were toxicity and overall survival (OS).Patients (pts) were treated with 6x E 60 mg/m2 and P 175 mg/m2 d1 q21d, or with 6× X 2×1000 mg/m2 d1–14 q 21d and P 175 mg/m2 d1 q21d. Results: During a period of 2.5 y the planned 340 pts (170 in each arm) in 63 centres were recruited. The median number of cycles was 6 in both arms. The median PFS for EP was 11.8 months, and 12.3 for XP (p=ns). OS also was not different between the arms. The response rate (RECIST) was 41.0% (CR 6.6%, PR 34.4%) for EP and 41.5% (CR 8.5%, PR 33.1%) for XP. The main toxicity was myelosuppression (10% of cycles grade 3/4). Febrile neutropenia was seen in 5 cases in EP and in 1 case in XP. Skin toxicity grade 3 was observed in 5 of XP pts. Two patients stopped treatment for cardiological reasons in EP, and 4 patients for GI reasons in XP. Conclusions: This first analysis shows a comparable efficacy of the non-anthracycline regimen XP to the EP combination in first-line MBC. The toxicity is relatively low compared to other non-anthracycline containing combination therapies. XP is therefore an appropriate option for pts with anthracycline pretreated first line MBC. [Table: see text]

Style APA, Harvard, Vancouver, ISO itp.

Artykuły w czasopismach na temat „XP”

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych